Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: UTR024
MIFTS: 60

Uterine Carcinosarcoma

Categories: Cancer diseases, Rare diseases, Reproductive diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Uterine Carcinosarcoma

About this section

MalaCards integrated aliases for Uterine Carcinosarcoma:

Name: Uterine Carcinosarcoma 12 54 60 56 6 15 17 74
Malignant Mixed Müllerian Tumor of the Corpus Uteri 54 60
Mixed Müllerian Cancer of Corpus Uteri 54 60
Carcinosarcoma of the Corpus Uteri 54 60
Malignant Mixed Müllerian Tumor of Corpus Uteri 54
Mixed Mullerian Sarcoma of Uterus 12
Uterine Corpus Carcinosarcoma 74

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)
ICD10: 35
Orphanet: 60  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 12 DOID:6171
NCIt 51 C42700
ICD10 via Orphanet 35 C54.9
Orphanet 60 ORPHA213610
Sources

Summaries for Uterine Carcinosarcoma

About this section
NIH Rare Diseases : 54 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 213610Disease definitionCarcinosarcoma of the corpus uteri is a rare, malignant, mixed epithelial and mesenchymal tumor of the uterine body composed of high-grade carcinomatous and sarcomatous elements. It may present with vaginal bleeding, abnormal vaginal discharge, abdominal pain and/or pelvic mass, with a polypoid tumor sometimes protruding through the cervical canal. Association with Tamoxifen therapy, long-term unopposed estrogen use and previous pelvic radiotherapy has been reported.Visit the Orphanet disease page for more resources.

MalaCards based summary : Uterine Carcinosarcoma, also known as malignant mixed müllerian tumor of the corpus uteri, is related to leiomyosarcoma and carcinosarcoma, and has symptoms including pelvic pain An important gene associated with Uterine Carcinosarcoma is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include uterus, lymph node and endothelial, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A uterine body mixed cancer that has material basis in both endometrial carcinoma and sarcoma.

Sources

Related Diseases for Uterine Carcinosarcoma

About this section

Diseases related to Uterine Carcinosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 234)
# Related Disease Score Top Affiliating Genes
1 leiomyosarcoma 31.0 KIT PGR TP53
2 carcinosarcoma 30.9 CTNNB1 ERBB2 HRAS KIT MME PGR
3 sarcoma 30.8 CTNNB1 HRAS KIT PIK3CA TP53
4 fallopian tube carcinoma 30.3 ERBB2 PGR TP53
5 endometrial stromal sarcoma 30.2 KIT MME PGR TP53
6 wilms tumor 1 30.1 CTNNB1 ERBB2 FBXW7 PGR TP53
7 cervical squamous cell carcinoma 30.0 CDH1 CTNNB1 TP53
8 adenosarcoma 29.9 KIT MME PGR TP53
9 chordoma 29.9 CDH1 EGFR PTEN
10 cervical cancer 29.1 CDH1 CTNNB1 ERBB2 HRAS PIK3CA PTEN
11 squamous cell carcinoma 28.5 CDH1 CTNNB1 EGFR ERBB2 FGFR2 HRAS
12 adenocarcinoma 28.2 CDH1 CTNNB1 EGFR ERBB2 ERBB3 FGFR2
13 colorectal cancer 28.0 CDH1 CTNNB1 EGFR ERBB2 ERBB3 ESR2
14 endometrial cancer 27.8 CDH1 CTNNB1 EGFR ERBB2 ESR2 FGFR2
15 breast cancer 27.4 CDH1 CTNNB1 EGFR ERBB2 ERBB3 ESR2
16 malignant spiradenoma 10.6 PIK3CA TP53
17 rare adenocarcinoma of the breast 10.6 PIK3CA TP53
18 gastric papillary adenocarcinoma 10.6 ERBB2 TP53
19 thyroid hurthle cell adenoma 10.6 PIK3CA PTEN
20 apocrine adenoma 10.6 HRAS PIK3CA
21 prostate adenoid cystic carcinoma 10.6 HRAS PIK3CA
22 endometrium carcinoma in situ 10.6 PGR TP53
23 prostate transitional cell carcinoma 10.6 CTNNB1 PIK3CA
24 intracystic papillary adenoma 10.6 ERBB2 PGR
25 scirrhous adenocarcinoma 10.6 ERBB2 PGR
26 thymoma, familial 10.6 HRAS KIT
27 breast metaplastic carcinoma 10.6 ERBB2 PGR
28 breast medullary carcinoma 10.5 ERBB2 PGR
29 breast apocrine carcinoma 10.5 ERBB2 PGR
30 glassy cell carcinoma of the cervix 10.5 ERBB2 PGR
31 bent bone dysplasia syndrome 10.5 ERBB2 FGFR2
32 immunodeficiency 14 10.5 PIK3R1 PTEN
33 protoplasmic astrocytoma 10.5 PTGS2 TP53
34 brain ependymoma 10.5 EGFR TP53
35 female breast cancer 10.5 ERBB2 PGR TP53
36 peutz-jeghers syndrome 10.5 CTNNB1 PTEN TP53
37 sweat gland cancer 10.5 ERBB2 PGR TP53
38 breast intraductal proliferative lesion 10.5 EGFR ERBB2
39 cell type benign neoplasm 10.4 CTNNB1 HRAS TP53
40 muscle cancer 10.4 KIT PGR TP53
41 anal squamous cell carcinoma 10.4 FBXW7 PIK3CA TP53
42 adult hepatocellular carcinoma 10.4 CTNNB1 PIK3CA TP53
43 synchronous bilateral breast carcinoma 10.4 PGR PTEN TP53
44 li-fraumeni syndrome 10.4 EGFR PTEN TP53
45 brain stem glioma 10.4 EGFR PIK3CA TP53
46 supratentorial cancer 10.4 EGFR PTEN TP53
47 giant cell glioblastoma 10.4 EGFR PTEN TP53
48 grade iii astrocytoma 10.4 EGFR PTEN TP53
49 nervous system cancer 10.4 EGFR PTEN TP53
50 central nervous system cancer 10.4 EGFR PTEN TP53

Graphical network of the top 20 diseases related to Uterine Carcinosarcoma:



Diseases related to Uterine Carcinosarcoma
Sources

Symptoms & Phenotypes for Uterine Carcinosarcoma

About this section

UMLS symptoms related to Uterine Carcinosarcoma:


pelvic pain

GenomeRNAi Phenotypes related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

27 (show all 46)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.72 EGFR HRAS PIK3CA
2 Decreased viability GR00106-A-0 10.72 ERBB3
3 Decreased viability GR00221-A-1 10.72 CDH1 KIT EGFR HRAS PIK3CA PIK3R1
4 Decreased viability GR00221-A-2 10.72 ERBB3 HRAS PIK3CA
5 Decreased viability GR00221-A-3 10.72 HRAS PIK3R1
6 Decreased viability GR00221-A-4 10.72 ERBB3 EGFR PIK3CA
7 Decreased viability GR00301-A 10.72 CDH1 ERBB3 FGFR2 KIT
8 Decreased viability GR00342-S-1 10.72 FGFR2
9 Decreased viability GR00342-S-2 10.72 ERBB3 FGFR2
10 Decreased viability GR00342-S-3 10.72 ERBB3 FGFR2
11 Decreased viability GR00402-S-2 10.72 CDH1 ERBB3 FGFR2 KIT EGFR HRAS
12 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.47 PIK3R1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.47 PIK3R1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.47 EGFR
15 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.47 EGFR FBXW7
16 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.47 FBXW7
17 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.47 FBXW7
18 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.47 FBXW7
19 Increased shRNA abundance (Z-score > 2) GR00366-A-158 10.47 SOX4
20 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.47 FBXW7 PIK3R1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-183 10.47 FBXW7 HRAS
22 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.47 EGFR
23 Increased shRNA abundance (Z-score > 2) GR00366-A-195 10.47 SOX4
24 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.47 HRAS
25 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.47 SOX4
26 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.47 PIK3R1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.47 EGFR
28 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.47 EGFR PIK3R1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.47 EGFR FBXW7 HRAS PIK3R1 SOX4
30 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.47 FBXW7
31 Increased shRNA abundance (Z-score > 2) GR00366-A-65 10.47 SOX4
32 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.47 SOX4
33 Increased shRNA abundance (Z-score > 2) GR00366-A-80 10.47 SOX4
34 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.47 HRAS
35 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.47 EGFR
36 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.47 PIK3R1
37 Decreased substrate adherent cell growth GR00193-A-1 10.03 ERBB3 KIT
38 Decreased substrate adherent cell growth GR00193-A-2 10.03 EGFR ERBB3 FGFR2 KIT
39 Decreased substrate adherent cell growth GR00193-A-3 10.03 FGFR2
40 Decreased substrate adherent cell growth GR00193-A-4 10.03 KIT
41 Increased cell death HMECs cells GR00103-A-0 10.02 CTNNB1 EGFR ERBB3 FBXW7 PGR PIK3CA
42 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 10 CTNNB1 EGFR ERBB2 FGFR2 HRAS PPP2R1A
43 Increased transferrin (TF) endocytosis GR00363-A 9.97 EGFR ERBB2 ESR2 FBXW7 HRAS KIT
44 Increased cell viability after pRB stimulation GR00230-A-1 9.62 EGFR ERBB2 ERBB3 KIT
45 Reduced mammosphere formation GR00396-S 9.56 CDH1 EGFR ERBB3 HRAS PIK3R1 PPP2R1A
46 Synthetic lethal with c-Myc after tamoxifen stimulation GR00215-A 9.02 CDH1 ERBB3 FBXW7 PTEN SOX4

MGI Mouse Phenotypes related to Uterine Carcinosarcoma:

47 (show all 28)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.58 CDH1 CTNNB1 EGFR ERBB2 ERBB3 ESR2
2 homeostasis/metabolism MP:0005376 10.57 CDH1 CTNNB1 EGFR ERBB2 ERBB3 ESR2
3 growth/size/body region MP:0005378 10.55 CDH1 CTNNB1 EGFR ERBB2 ERBB3 ESR2
4 cellular MP:0005384 10.53 CDH1 CTNNB1 EGFR ERBB2 ERBB3 ESR2
5 endocrine/exocrine gland MP:0005379 10.53 CDH1 CTNNB1 EGFR ERBB2 ERBB3 ESR2
6 behavior/neurological MP:0005386 10.51 CTNNB1 ERBB2 ERBB3 ESR2 FGFR2 HRAS
7 integument MP:0010771 10.5 CDH1 CTNNB1 EGFR ERBB2 ERBB3 ESR2
8 digestive/alimentary MP:0005381 10.49 CDH1 CTNNB1 EGFR ERBB2 ERBB3 ESR2
9 immune system MP:0005387 10.49 CDH1 CTNNB1 EGFR ERBB3 ESR2 FBXW7
10 mortality/aging MP:0010768 10.49 CDH1 CTNNB1 EGFR ERBB2 ERBB3 ESR2
11 embryo MP:0005380 10.48 CDH1 CTNNB1 EGFR ERBB2 ERBB3 FBXW7
12 neoplasm MP:0002006 10.41 CDH1 CTNNB1 EGFR ERBB2 ERBB3 ESR2
13 hematopoietic system MP:0005397 10.39 CTNNB1 EGFR ESR2 FBXW7 FGFR2 KIT
14 nervous system MP:0003631 10.33 CTNNB1 EGFR ERBB2 ERBB3 ESR2 FBXW7
15 normal MP:0002873 10.33 CDH1 CTNNB1 EGFR ERBB2 ERBB3 ESR2
16 craniofacial MP:0005382 10.32 CTNNB1 EGFR ERBB2 FBXW7 FGFR2 HRAS
17 muscle MP:0005369 10.31 CTNNB1 EGFR ERBB2 ERBB3 ESR2 FGFR2
18 liver/biliary system MP:0005370 10.26 CTNNB1 EGFR ESR2 FBXW7 FGFR2 KIT
19 adipose tissue MP:0005375 10.24 EGFR ESR2 FGFR2 PIK3CA PIK3R1 PTEN
20 limbs/digits/tail MP:0005371 10.24 CTNNB1 EGFR ERBB2 ESR2 FGFR2 KIT
21 no phenotypic analysis MP:0003012 10.17 CDH1 CTNNB1 EGFR ESR2 FGFR2 HRAS
22 reproductive system MP:0005389 10.07 CDH1 CTNNB1 EGFR ERBB2 ESR2 FGFR2
23 hearing/vestibular/ear MP:0005377 10.06 CTNNB1 EGFR ESR2 FGFR2 KIT TP53
24 renal/urinary system MP:0005367 10.02 CTNNB1 EGFR ESR2 FGFR2 HRAS KIT
25 pigmentation MP:0001186 9.97 CTNNB1 EGFR ERBB3 FGFR2 KIT PTEN
26 respiratory system MP:0005388 9.97 CTNNB1 EGFR ERBB2 ERBB3 ESR2 FBXW7
27 skeleton MP:0005390 9.8 CTNNB1 EGFR ERBB2 ESR2 FGFR2 HRAS
28 vision/eye MP:0005391 9.36 CTNNB1 EGFR FBXW7 FGFR2 KIT PIK3CA
Sources

Drugs & Therapeutics for Uterine Carcinosarcoma

About this section

Drugs for Uterine Carcinosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 78)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
2
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 38904 10339178 498142
3
Ifosfamide Approved Phase 3 3778-73-2 3690
4
Lenograstim Approved, Investigational Phase 3 135968-09-1
5
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
6
Cisplatin Approved Phase 3 15663-27-1 441203 84093 2767
7
Mesna Approved, Investigational Phase 3 3375-50-6 598
8
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
9
Histamine Approved, Investigational Phase 3 51-45-6 774
10
Cyproheptadine Approved Phase 3 129-03-3 2913
11
Doxil Approved June 1999 Phase 3,Phase 2 31703
12 Antineoplastic Agents, Alkylating Phase 3,Phase 2
13 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1,Not Applicable
14 Alkylating Agents Phase 3,Phase 2
15 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
16 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
17
Isophosphamide mustard Phase 3 0
18 Anti-Bacterial Agents Phase 3,Phase 2
19 Antibiotics, Antitubercular Phase 3,Phase 2
20 Topoisomerase Inhibitors Phase 3,Phase 2
21
Histamine Phosphate Phase 3 51-74-1 65513
22 Anti-Allergic Agents Phase 3
23 Neurotransmitter Agents Phase 3
24 Histamine H1 Antagonists Phase 3
25 Serotonin Agents Phase 3
26 Serotonin Antagonists Phase 3
27 Antipruritics Phase 3
28 Dermatologic Agents Phase 3
29 Gastrointestinal Agents Phase 3
30 Histamine Antagonists Phase 3
31
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
32
Gemcitabine Approved Phase 2 95058-81-4 60750
33
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
34
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
35
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
36
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
37
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
38
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
39
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
40
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
41
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
42
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
43
Metformin Approved Phase 2 657-24-9 14219 4091
44
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60700
45
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
46
Iniparib Investigational Phase 2 160003-66-7
47
Saracatinib Investigational Phase 2 379231-04-6
48 Antimetabolites, Antineoplastic Phase 2
49 Immunologic Factors Phase 2,Phase 1
50 Immunosuppressive Agents Phase 2

Interventional clinical trials:

(show all 42)
# Name Status NCT ID Phase Drugs
1 Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus Completed NCT00003128 Phase 3 ifosfamide;paclitaxel
2 Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus Completed NCT00002459 Phase 3
3 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus Completed NCT00002546 Phase 3 cisplatin;ifosfamide
4 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
5 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
6 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Active, not recruiting NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
7 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
8 Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble - Unknown status NCT02203760 Phase 2 Pazopanib plus Gemcitabine;Pazopanib
9 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
10 Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma Completed NCT00687687 Phase 2 paclitaxel;carboplatin;BSI-201 (Iniparib)
11 Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00025506 Phase 2 Thalidomide
12 Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT01247571 Phase 2 Pazopanib Hydrochloride
13 Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT01168232 Phase 2 Ixabepilone
14 Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00114218 Phase 2 Gemcitabine Hydrochloride;Docetaxel
15 Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00075400 Phase 2 imatinib mesylate
16 Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer Completed NCT00112489 Phase 2 carboplatin;paclitaxel
17 Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer Completed NCT00238121 Phase 2 sorafenib tosylate
18 Chemotherapy in Treating Patients With Sarcoma of the Uterus Completed NCT00005643 Phase 2 pegylated liposomal doxorubicin hydrochloride
19 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
20 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
21 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Completed NCT00390234 Phase 2 ziv-aflibercept
22 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
23 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
24 Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract Completed NCT00003334 Phase 2 paclitaxel;pegylated liposomal doxorubicin hydrochloride
25 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
26 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
27 Thalidomide in Treating Patients With Gynecologic Sarcomas Completed NCT00006005 Phase 2 thalidomide
28 Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2 PegLiposomal Doxorubicin;Carboplatin
29 Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer Recruiting NCT02874430 Phase 2 Metformin Hydrochloride;Doxycycline
30 Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Active, not recruiting NCT00478426 Phase 2 Sunitinib Malate
31 Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Active, not recruiting NCT01935934 Phase 2 Cabozantinib S-malate
32 Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)_MITO 26 Not yet recruiting NCT02993705 Phase 2 Trabectedin
33 Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus Terminated NCT01061606 Phase 2 temsirolimus
34 Topotecan in Treating Patients With Recurrent or Refractory Cancer of the Uterus Terminated NCT00003156 Phase 2 topotecan hydrochloride
35 Vorinostat (SAHA) in Uterine Sarcoma Terminated NCT03509207 Phase 2 Vorinostat Oral Capsule
36 Suitability of DCE-MRI for Detection of Vascular Changes After VBT Unknown status NCT01991808 Phase 1
37 Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary Recruiting NCT03206177 Phase 1 Galunisertib;Paclitaxel;Carboplatin
38 Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Recruiting NCT03552471 Phase 1 Rucaparib Camsylate
39 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Recruiting NCT02020707 Phase 1 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
40 Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer Unknown status NCT01367301 Not Applicable paclitaxel;carboplatin
41 Lymph Node Counts in Endometrial Cancer Staging Completed NCT02335775
42 Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological Cancer Withdrawn NCT03902379 Not Applicable

Search NIH Clinical Center for Uterine Carcinosarcoma

Sources

Genetic Tests for Uterine Carcinosarcoma

About this section
Sources

Anatomical Context for Uterine Carcinosarcoma

About this section

MalaCards organs/tissues related to Uterine Carcinosarcoma:

42
Uterus, Lymph Node, Endothelial, Ovary, Colon
Sources

Publications for Uterine Carcinosarcoma

About this section

Articles related to Uterine Carcinosarcoma:

(show top 50) (show all 201)
# Title Authors Year
1
Immunohistochemical analysis of the epithelial to mesenchymal transition in uterine carcinosarcoma. ( 30636710 )
2019
2
Cytological features of uterine carcinosarcoma: A retrospective study of 20 cases with an emphasis on the usefulness of endometrial cytology. ( 30706679 )
2019
3
Effect of Adjuvant Therapy on Oncologic Outcomes of Surgically Approved Stage I Uterine Carcinosarcoma: Turkish Gynecologic Oncology Study ( 30873825 )
2019
4
Lymphadenectomy and Adjuvant Therapy Improve Survival with Uterine Carcinosarcoma: A Large Retrospective Cohort Study. ( 29791913 )
2018
5
Significance of Lymphovascular Space Invasion by the Sarcomatous Component in Uterine Carcinosarcoma. ( 29971677 )
2018
6
Fluorodeoxyglucose Positron Emission Tomography-computed Tomography Evaluation of an Interesting Case of Uterine Carcinosarcoma with Isolated Appendicular Skeletal Metastases. ( 29643680 )
2018
7
Trends of uterine carcinosarcoma in the United States. ( 29400015 )
2018
8
Tumor Mutational Burden Guides Therapy in a Treatment Refractory<i>POLE-</i>Mutant Uterine Carcinosarcoma. ( 29386312 )
2018
9
The Association of an Elevated Thrombocyte Count with Clinicopathological Prognostic Factors and Survival in Patients with Uterine Carcinosarcoma. ( 29629727 )
2018
10
Diagnostic accuracy of 3.0T diffusion-weighted MRI for patients with uterine carcinosarcoma: Assessment of tumor extent and lymphatic metastasis. ( 29437265 )
2018
11
Insulin-like growth factor 2: a poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma. ( 29455465 )
2018
12
Prognostic Significance of omental Disease and the Role of Omental Sampling in Patients With Uterine Carcinosarcoma. ( 29303931 )
2018
13
Significance of venous thromboembolism in women with uterine carcinosarcoma. ( 29248197 )
2018
14
Impact of radiotherapy modalities on outcomes in the adjuvant management of uterine carcinosarcoma: A National Cancer Database analysis. ( 29097136 )
2018
15
Uterine Carcinosarcoma with Alpha-Fetoprotein-Producing Hepatoid Component: A Case Report and Literature Review. ( 29992073 )
2018
16
A Case of Uterine Carcinosarcoma Detected Simultaneously with Breast and Colon Cancer (Triple Primary Malignant Tumor). ( 30057538 )
2018
17
Proposal for a Risk-Based Categorization of Uterine Carcinosarcoma. ( 30105438 )
2018
18
L1CAM expression in uterine carcinosarcoma is limited to the epithelial component and may be involved in epithelial-mesenchymal transition. ( 30140948 )
2018
19
Clinical utility of CA-125 in the management of uterine carcinosarcoma. ( 30207096 )
2018
20
Characterizing sarcoma dominance pattern in uterine carcinosarcoma: Homologous versus heterologous element. ( 30217299 )
2018
21
Radiation-Induced Uterine Carcinosarcoma after Concurrent Chemoradiotherapy for Cervical Squamous Cell Carcinoma. ( 30308682 )
2018
22
Uterine carcinosarcoma (malignant mixed Müllerian tumor): case report in a goat and literature review. ( 30345891 )
2018
23
Molecular classification and subtype-specific drug sensitivity research of uterine carcinosarcoma under multi-omics framework. ( 30359167 )
2018
24
Prognostic factors impacting survival in early stage uterine carcinosarcoma. ( 30414738 )
2018
25
Ultrasonographic Findings of Uterine Carcinosarcoma. ( 30504724 )
2018
26
Diagnostic Value of 18F-FDG PET/CT and MRI in the Preoperative Evaluation of Uterine Carcinosarcoma. ( 30538776 )
2018
27
Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma. ( 29056442 )
2017
28
Identification of distinct molecular subtypes of uterine carcinosarcoma. ( 28178664 )
2017
29
Stage I uterine carcinosarcoma: Matched cohort analyses for lymphadenectomy, chemotherapy, and brachytherapy. ( 28317560 )
2017
30
Prognostic value of metabolic parameters determined by preoperative A^a8,F-FDG PET/CT in patients with uterine carcinosarcoma. ( 28541634 )
2017
31
Role of Radiation Therapy in the Multidisciplinary Management of Uterine Carcinosarcoma. ( 28930812 )
2017
32
Port-Site Metastasis of Uterine Carcinosarcoma after Laparoscopy. ( 28960047 )
2017
33
Prognostic factors for disease-free and overall survival of patients with uterine carcinosarcoma. ( 28836024 )
2017
34
Durable complete remission with aromatase inhibitor therapy in a patient with metastatic uterine carcinosarcoma with poor performance status and coagulation disorders: a case report. ( 28424084 )
2017
35
Use of Adjuvant Chemotherapy, Radiation Therapy, or Combined Modality Therapy and the Impact on Survival for Uterine Carcinosarcoma Limited to the Pelvis. ( 28574930 )
2017
36
Integrated Molecular Characterization of Uterine Carcinosarcoma. ( 28292439 )
2017
37
Survival outcome of women with stage IV uterine carcinosarcoma who received neoadjuvant chemotherapy followed by surgery. ( 29044542 )
2017
38
Chemoradiation Versus Chemotherapy in Uterine Carcinosarcoma: Patterns of Care and Impact on Overall Survival. ( 28121642 )
2017
39
Tumor characteristics and survival outcomes of women with tamoxifen-related uterine carcinosarcoma. ( 27931750 )
2017
40
Whole-Genome DNA Methylation Profiling Identifies Epigenetic Signatures of Uterine Carcinosarcoma. ( 28088687 )
2017
41
Unenhanced region on magnetic resonance imaging represents tumor progression in uterine carcinosarcoma. ( 28657223 )
2017
42
Fascin Is Associated With Aggressive Behavior and Poor Outcome in Uterine Carcinosarcoma. ( 28704324 )
2017
43
Secondary uterine carcinosarcoma after concurrent chemoradiotherapy for cervical cancer: Case reports. ( 28761924 )
2017
44
Patterns of Adjuvant Therapy Utilization in Uterine Carcinosarcoma Stages I to III: A National Cancer Database Analysis. ( 28654573 )
2017
45
Functional role of ALK-related signal cascades on modulation of epithelial-mesenchymal transition and apoptosis in uterine carcinosarcoma. ( 28193280 )
2017
46
A predictive diagnostic model using multiparametric MRI for differentiating uterine carcinosarcoma from carcinoma of the uterine corpus. ( 28584958 )
2017
47
Stage I uterine carcinosarcoma: Matched cohort analyses for lymphadenectomy, chemotherapy, and brachytherapy. ( 28318642 )
2017
48
Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma. ( 28215838 )
2017
49
Genetic Investigation of Uterine Carcinosarcoma: Case Report and Cohort Analysis. ( 27009459 )
2016
50
Adjuvant radiation therapy in uterine carcinosarcoma: A population-based analysis of patient demographic and clinical characteristics, patterns of care and outcomes. ( 26896827 )
2016
Sources

Variations for Uterine Carcinosarcoma

About this section

ClinVar genetic disease variations for Uterine Carcinosarcoma:

6 (show top 50) (show all 350)
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_001126115.1(TP53): c.443G> T (p.Arg148Ile) single nucleotide variant Uncertain significance rs121912660 GRCh38 Chromosome 17, 7673781: 7673781
2 TP53 NM_001126115.1(TP53): c.443G> T (p.Arg148Ile) single nucleotide variant Uncertain significance rs121912660 GRCh37 Chromosome 17, 7577099: 7577099
3 TP53 NM_001126115.1(TP53): c.401G> A (p.Gly134Glu) single nucleotide variant Conflicting interpretations of pathogenicity rs193920774 GRCh38 Chromosome 17, 7673823: 7673823
4 TP53 NM_001126115.1(TP53): c.401G> A (p.Gly134Glu) single nucleotide variant Conflicting interpretations of pathogenicity rs193920774 GRCh37 Chromosome 17, 7577141: 7577141
5 TP53 NM_000546.5(TP53): c.722C> G (p.Ser241Cys) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
6 TP53 NM_000546.5(TP53): c.722C> G (p.Ser241Cys) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
7 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh38 Chromosome 17, 7673778: 7673778
8 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
9 TP53 NM_000546.5(TP53): c.713G> A (p.Cys238Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs730882005 GRCh38 Chromosome 17, 7674250: 7674250
10 TP53 NM_000546.5(TP53): c.713G> A (p.Cys238Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs730882005 GRCh37 Chromosome 17, 7577568: 7577568
11 TP53 NM_000546.5(TP53): c.646G> A (p.Val216Met) single nucleotide variant Conflicting interpretations of pathogenicity rs730882025 GRCh38 Chromosome 17, 7674885: 7674885
12 TP53 NM_000546.5(TP53): c.646G> A (p.Val216Met) single nucleotide variant Conflicting interpretations of pathogenicity rs730882025 GRCh37 Chromosome 17, 7578203: 7578203
13 TP53 NM_000546.5(TP53): c.578A> T (p.His193Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs786201838 GRCh37 Chromosome 17, 7578271: 7578271
14 TP53 NM_000546.5(TP53): c.578A> T (p.His193Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs786201838 GRCh38 Chromosome 17, 7674953: 7674953
15 TP53 NM_000546.5(TP53): c.578A> G (p.His193Arg) single nucleotide variant Likely pathogenic rs786201838 GRCh37 Chromosome 17, 7578271: 7578271
16 TP53 NM_000546.5(TP53): c.578A> G (p.His193Arg) single nucleotide variant Likely pathogenic rs786201838 GRCh38 Chromosome 17, 7674953: 7674953
17 TP53 NM_000546.5(TP53): c.487T> G (p.Tyr163Asp) single nucleotide variant Likely pathogenic rs786203436 GRCh37 Chromosome 17, 7578443: 7578443
18 TP53 NM_000546.5(TP53): c.487T> G (p.Tyr163Asp) single nucleotide variant Likely pathogenic rs786203436 GRCh38 Chromosome 17, 7675125: 7675125
19 PPP2R1A NM_014225.5(PPP2R1A): c.536C> T (p.Pro179Leu) single nucleotide variant Pathogenic rs786205228 GRCh38 Chromosome 19, 52212718: 52212718
20 PPP2R1A NM_014225.5(PPP2R1A): c.536C> T (p.Pro179Leu) single nucleotide variant Pathogenic rs786205228 GRCh37 Chromosome 19, 52715971: 52715971
21 TP53 NM_000546.5(TP53): c.584T> C (p.Ile195Thr) single nucleotide variant Pathogenic rs760043106 GRCh38 Chromosome 17, 7674947: 7674947
22 TP53 NM_000546.5(TP53): c.584T> C (p.Ile195Thr) single nucleotide variant Pathogenic rs760043106 GRCh37 Chromosome 17, 7578265: 7578265
23 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh37 Chromosome 3, 178936093: 178936093
24 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh38 Chromosome 3, 179218305: 179218305
25 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
26 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh38 Chromosome 10, 87933148: 87933148
27 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
28 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
29 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
30 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
31 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
32 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh38 Chromosome 17, 7674238: 7674238
33 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
34 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh38 Chromosome 17, 7674229: 7674229
35 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
36 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
37 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
38 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
39 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
40 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
41 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
42 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
43 TP53 NM_000546.5(TP53): c.839G> C (p.Arg280Thr) single nucleotide variant Uncertain significance rs121912660 GRCh37 Chromosome 17, 7577099: 7577099
44 TP53 NM_000546.5(TP53): c.839G> C (p.Arg280Thr) single nucleotide variant Uncertain significance rs121912660 GRCh38 Chromosome 17, 7673781: 7673781
45 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
46 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
47 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
48 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
49 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
50 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh38 Chromosome 17, 7674872: 7674872
Sources

Expression for Uterine Carcinosarcoma

About this section
Search GEO for disease gene expression data for Uterine Carcinosarcoma.
Sources

Pathways for Uterine Carcinosarcoma

About this section

Pathways related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 152)
# Super pathways Score Top Affiliating Genes
1
Signaling by GPCR 67
Show member pathways
 14.29 CDH1 CTNNB1 EGFR ERBB2 ERBB3 FBXW7
2
Innate Immune System 67
Show member pathways
 14.13 CDH1 CTNNB1 EGFR ERBB2 ERBB3 FBXW7
3
Apoptotic Pathways in Synovial Fibroblasts 65
Show member pathways
 13.99 EGFR ERBB2 ERBB3 FGFR2 HRAS KIT
4
ERK Signaling 65
Show member pathways
 13.96 CDH1 CTNNB1 EGFR ERBB2 ERBB3 ESR2
5
GPCR Pathway 65
Show member pathways
 13.86 EGFR ERBB2 ERBB3 ESR2 FGFR2 HRAS
6
HIV Life Cycle 67
Show member pathways
 13.86 CDH1 CTNNB1 EGFR ERBB2 ERBB3 FBXW7
7
PEDF Induced Signaling 65
Show member pathways
 13.82 EGFR ERBB2 ERBB3 FGFR2 HRAS KIT
8
TGF-Beta Pathway 65
Show member pathways
 13.69 CDH1 EGFR ERBB2 ERBB3 FGFR2 HRAS
9
Activation of cAMP-Dependent PKA 65
Show member pathways
 13.67 CTNNB1 EGFR ERBB2 ERBB3 FGFR2 HRAS
10
Developmental Biology 67
Show member pathways
 13.65 CTNNB1 EGFR ERBB2 ERBB3 FGFR2 HRAS
11
Class I MHC mediated antigen processing and presentation 67
Show member pathways
 13.59 CDH1 EGFR ERBB2 ERBB3 FBXW7 FGFR2
12
Akt Signaling 65
Show member pathways
 13.56 EGFR ERBB2 ERBB3 FGFR2 HRAS KIT
13
Cytokine Signaling in Immune system 67
Show member pathways
 13.5 EGFR ERBB2 ERBB3 FGFR2 HRAS KIT
14
CREB Pathway 65
Show member pathways
 13.46 EGFR ERBB2 ERBB3 FGFR2 HRAS KIT
15
PAK Pathway 65
Show member pathways
 13.44 CDH1 CTNNB1 EGFR ERBB2 FGFR2 HRAS
16
Nanog in Mammalian ESC Pluripotency 65
Show member pathways
 13.41 CDH1 CTNNB1 EGFR ERBB2 ERBB3 ESR2
17
IL-2 Pathway 65
Show member pathways
 13.34 EGFR ERBB2 ERBB3 HRAS PIK3R1 PTEN
18
Phospholipase-C Pathway 65
Show member pathways
 13.21 EGFR FGFR2 HRAS KIT PIK3R1 PTEN
19
p70S6K Signaling 65
Show member pathways
 13.19 EGFR FGFR2 HRAS KIT PIK3R1 PPP2R1A
20
Circadian entrainment 38
Show member pathways
 13.18 EGFR ESR2 HRAS PGR PIK3CA PIK3R1
21
Actin Nucleation by ARP-WASP Complex 65
Show member pathways
 13.13 CDH1 EGFR ERBB2 ERBB3 FGFR2 HRAS
22
Human cytomegalovirus infection 38
Show member pathways
 13.12 CTNNB1 EGFR HRAS PIK3CA PIK3R1 PTEN
23
TNFR1 Pathway 65
Show member pathways
 13.1 CTNNB1 EGFR HRAS PIK3CA PIK3R1 PTEN
24
Sertoli-Sertoli Cell Junction Dynamics 65
Show member pathways
 13.06 CDH1 CTNNB1 HRAS PIK3R1 PPP2R1A PTEN
25
Regulation of lipid metabolism Insulin signaling-generic cascades 23
Show member pathways
 13.06 EGFR ERBB2 ERBB3 HRAS PIK3CA PIK3R1
26
Focal Adhesion 1 38
Show member pathways
 13.06 CTNNB1 EGFR ERBB2 HRAS PIK3CA PIK3R1
27
Development Angiotensin activation of ERK 23
Show member pathways
 13.04 EGFR HRAS KIT PIK3CA PIK3R1 TP53
28
NFAT and Cardiac Hypertrophy 65
Show member pathways
 13.03 EGFR ERBB2 ERBB3 FGFR2 HRAS PIK3CA
29
PI3K-Akt signaling pathway 38
Show member pathways
 12.97 CTNNB1 EGFR ERBB2 ERBB3 FGFR2 HRAS
30
Endometrial cancer 38
Show member pathways
 12.94 CDH1 CTNNB1 EGFR ERBB2 FGFR2 HRAS
31
MAPK signaling pathway 1 38
12.93 EGFR ERBB2 ERBB3 FGFR2 HRAS KIT
32
Ras signaling pathway 38
Show member pathways
 12.89 CDH1 CTNNB1 EGFR FGFR2 HRAS KIT
33
Development HGF signaling pathway 23
Show member pathways
 12.84 CDH1 CTNNB1 ERBB2 ERBB3 HRAS PIK3CA
34
Development Endothelin-1/EDNRA signaling 23
Show member pathways
 12.82 CTNNB1 EGFR HRAS PIK3CA PIK3R1 PTEN
35
4-1BB Pathway 65
Show member pathways
 12.8 EGFR HRAS PIK3R1 PPP2R1A TP53
36
Glioma 38
Show member pathways
 12.77 CDH1 EGFR ERBB2 ERBB3 ESR2 FGFR2
37
Regulation of actin cytoskeleton 38 1
12.76 EGFR FGFR2 HRAS PIK3CA PIK3R1
38
Immune response IL-23 signaling pathway 23
Show member pathways
 12.76 CTNNB1 EGFR ERBB2 HRAS PIK3CA PIK3R1
39
ErbB signaling pathway 1 38
Show member pathways
 12.76 EGFR ERBB2 ERBB3 HRAS PIK3CA PIK3R1
40
Downstream signaling events of B Cell Receptor (BCR) 67
Show member pathways
 12.75 EGFR ERBB2 ERBB3 FGFR2 HRAS KIT
41
Immune response Fc epsilon RI pathway 23
Show member pathways
 12.72 HRAS PIK3CA PIK3R1 PTEN PTGS2
42
Development Dopamine D2 receptor transactivation of EGFR 23
Show member pathways
 12.71 EGFR HRAS PIK3CA PIK3R1 PPP2R1A
43
MicroRNAs in cancer 38
12.67 EGFR ERBB2 ERBB3 HRAS PIK3CA PTEN
44
Prolactin Signaling Pathway 1 38
Show member pathways
 12.66 ERBB2 ESR2 HRAS PIK3CA PIK3R1 PTEN
45
mTOR signaling pathway (KEGG) 66
Show member pathways
 12.64 EGFR ERBB2 ERBB3 FGFR2 HRAS PIK3CA
46
Gastric cancer 38
Show member pathways
 12.64 CDH1 CTNNB1 EGFR ERBB2 ESR2 FGFR2
47
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.59 HRAS PIK3CA PIK3R1 PPP2R1A TP53
48
Phospholipase D signaling pathway 38
Show member pathways
 12.56 EGFR HRAS KIT PIK3CA PIK3R1
49
Development VEGF signaling via VEGFR2 - generic cascades 23
Show member pathways
 12.55 CTNNB1 HRAS PIK3CA PIK3R1 PTGS2
50
Apoptosis Pathway 73
Show member pathways
 12.55 CTNNB1 EGFR ERBB2 ERBB3 FGFR2 HRAS
Sources

GO Terms for Uterine Carcinosarcoma

About this section

Cellular components related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 perinuclear region of cytoplasm GO:0048471 9.85 CDH1 CTNNB1 EGFR ERBB2 FBXW7 HRAS
2 basolateral plasma membrane GO:0016323 9.76 CTNNB1 EGFR ERBB2 ERBB3
3 cytoplasmic side of plasma membrane GO:0009898 9.58 CDH1 KIT PTEN
4 cytoplasm GO:0005737 9.58 CDH1 CTNNB1 EGFR ERBB2 FBXW7 FGFR2
5 receptor complex GO:0043235 9.55 EGFR ERBB2 ERBB3 FGFR2 KIT
6 basal plasma membrane GO:0009925 9.5 EGFR ERBB2 ERBB3
7 flotillin complex GO:0016600 9.48 CDH1 CTNNB1
8 phosphatidylinositol 3-kinase complex, class IA GO:0005943 9.26 PIK3CA PIK3R1
9 lateral plasma membrane GO:0016328 9.26 CDH1 CTNNB1 ERBB3 PPP2R1A
10 nucleus GO:0005634 10.34 CTNNB1 EGFR ERBB2 ESR2 FBXW7 FGFR2
11 plasma membrane GO:0005886 10.25 CDH1 CTNNB1 EGFR ERBB2 ERBB3 FGFR2

Biological processes related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Name GO ID Score Top Affiliating Genes
1 protein stabilization GO:0050821 9.99 FBXW7 PIK3R1 PTEN SOX4
2 peptidyl-tyrosine phosphorylation GO:0018108 9.96 EGFR ERBB2 ERBB3 FGFR2 KIT
3 positive regulation of DNA-binding transcription factor activity GO:0051091 9.95 CTNNB1 ESR2 KIT PTEN
4 regulation of cell proliferation GO:0042127 9.95 CTNNB1 EGFR ERBB3 KIT PTGS2
5 response to estradiol GO:0032355 9.94 CTNNB1 EGFR PTEN PTGS2
6 MAPK cascade GO:0000165 9.93 EGFR ERBB2 ERBB3 FGFR2 HRAS KIT
7 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.92 EGFR ERBB2 ERBB3 KIT
8 wound healing GO:0042060 9.92 EGFR ERBB2 ERBB3 FGFR2
9 lung development GO:0030324 9.91 CTNNB1 EGFR FBXW7 FGFR2
10 response to organic substance GO:0010033 9.91 CDH1 PPP2R1A PTEN PTGS2
11 positive regulation of protein kinase B signaling GO:0051897 9.91 EGFR ERBB2 ERBB3 FGFR2 KIT PIK3CA
12 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.9 EGFR PIK3CA PTGS2
13 cellular response to growth factor stimulus GO:0071363 9.89 CTNNB1 EGFR ERBB2
14 positive regulation of smooth muscle cell proliferation GO:0048661 9.88 EGFR FGFR2 PTGS2
15 phosphatidylinositol-3-phosphate biosynthetic process GO:0036092 9.88 FGFR2 PIK3CA PIK3R1
16 epidermal growth factor receptor signaling pathway GO:0007173 9.87 EGFR PIK3CA PIK3R1
17 cellular response to UV GO:0034644 9.87 PIK3R1 PTGS2 TP53
18 cell differentiation GO:0030154 9.87 CTNNB1 EGFR SOX4 TP53
19 cellular response to epidermal growth factor stimulus GO:0071364 9.86 EGFR ERBB2 SNAI2
20 T cell differentiation GO:0030217 9.85 CTNNB1 KIT SOX4
21 epithelial to mesenchymal transition GO:0001837 9.85 CTNNB1 FGFR2 SNAI2
22 response to radiation GO:0009314 9.85 KIT PTGS2 SNAI2
23 positive regulation of protein import into nucleus GO:0042307 9.83 CDH1 PIK3R1 PTGS2
24 regulation of cell motility GO:2000145 9.83 EGFR ERBB2 ERBB3
25 positive regulation of epithelial cell proliferation GO:0050679 9.83 EGFR ERBB2 FGFR2 HRAS
26 regulation of ERK1 and ERK2 cascade GO:0070372 9.82 EGFR ERBB2 FGFR2
27 vasculature development GO:0001944 9.81 CTNNB1 FBXW7 PIK3CA
28 positive regulation of MAP kinase activity GO:0043406 9.81 EGFR ERBB2 HRAS KIT
29 morphogenesis of embryonic epithelium GO:0016331 9.73 CTNNB1 FGFR2
30 phosphatidylinositol 3-kinase signaling GO:0014065 9.73 ERBB2 ERBB3 PIK3CA PIK3R1
31 tongue development GO:0043586 9.72 EGFR KIT
32 limb bud formation GO:0060174 9.72 FGFR2 SOX4
33 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.72 EGFR TP53
34 ERBB2 signaling pathway GO:0038128 9.72 EGFR ERBB2 ERBB3 PIK3CA PIK3R1
35 entry of bacterium into host cell GO:0035635 9.71 CDH1 CTNNB1
36 lung-associated mesenchyme development GO:0060484 9.71 CTNNB1 FGFR2
37 regulation of osteoblast differentiation GO:0045667 9.71 CTNNB1 FGFR2 SNAI2
38 negative regulation of ERBB signaling pathway GO:1901185 9.7 EGFR ERBB2
39 cellular response to indole-3-methanol GO:0071681 9.69 CDH1 CTNNB1
40 mesenchymal cell proliferation involved in lung development GO:0060916 9.67 CTNNB1 FGFR2
41 positive regulation of MAPK cascade GO:0043410 9.65 CTNNB1 ERBB2 FGFR2 HRAS KIT
42 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.63 EGFR FBXW7 FGFR2 HRAS KIT PTEN
43 phosphatidylinositol phosphorylation GO:0046854 9.5 EGFR ERBB2 ERBB3 FGFR2 KIT PIK3CA
44 negative regulation of signal transduction GO:0009968 9.19 ERBB3
45 negative regulation of apoptotic process GO:0043066 9.17 CTNNB1 EGFR PIK3R1 PTEN PTGS2 SNAI2
46 signal transduction GO:0007165 10.33 EGFR ERBB2 ERBB3 ESR2 HRAS KIT
47 positive regulation of transcription by RNA polymerase II GO:0045944 10.23 CTNNB1 EGFR FGFR2 HRAS PGR PIK3R1
48 phosphorylation GO:0016310 10.18 EGFR ERBB2 ERBB3 FGFR2 KIT PIK3CA
49 positive regulation of transcription, DNA-templated GO:0045893 10.16 CDH1 CTNNB1 EGFR ESR2 SOX4 TP53
50 protein phosphorylation GO:0006468 10.13 EGFR ERBB2 ERBB3 FGFR2 KIT PIK3CA

Molecular functions related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.95 EGFR ERBB2 ERBB3 FGFR2 HRAS KIT
2 enzyme binding GO:0019899 9.91 CTNNB1 EGFR ESR2 PGR PTEN PTGS2
3 protein heterodimerization activity GO:0046982 9.86 CTNNB1 EGFR ERBB2 ERBB3 PIK3R1 PPP2R1A
4 protein tyrosine kinase activity GO:0004713 9.85 EGFR ERBB2 ERBB3 FGFR2 KIT
5 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.8 EGFR ERBB2 ERBB3 FGFR2 KIT
6 protein phosphatase binding GO:0019903 9.72 CTNNB1 EGFR ERBB2 PIK3R1 TP53
7 1-phosphatidylinositol-3-kinase activity GO:0016303 9.7 FGFR2 PIK3CA PIK3R1
8 transmembrane signaling receptor activity GO:0004888 9.67 EGFR ERBB2 ERBB3
9 insulin receptor substrate binding GO:0043560 9.55 PIK3CA PIK3R1
10 ErbB-3 class receptor binding GO:0043125 9.51 ERBB2 PIK3R1
11 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.35 EGFR ERBB2 ERBB3 FGFR2 KIT
12 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.17 EGFR ERBB2 ERBB3 FGFR2 KIT PIK3CA
13 protein binding GO:0005515 10.16 CDH1 CTNNB1 EGFR ERBB2 ERBB3 ESR2
14 identical protein binding GO:0042802 10.09 CDH1 EGFR ERBB2 ERBB3 ESR2 FBXW7
15 kinase activity GO:0016301 10.01 EGFR ERBB2 ERBB3 FGFR2 KIT PIK3CA
Sources

Sources for Uterine Carcinosarcoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....